

AMENDMENTS TO THE CLAIMS

1. – 4. (Canceled)

5. (Currently Amended) ~~The A compound of formula [I] as defined in claim 4, which~~
is selected from the group consisting of

- (1) 4'-[(2R)-2-[[(2R)-2-Phenyl-2-hydroxyethyl]amino]propyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid,
- (2) 4'-[(2R)-2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]-3-isopropoxy-1,1'-biphenyl-4-carboxylic acid,
- (3) 4'-[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid,
- (4) 4'-[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]-2,3-dimethyl-1,1'-biphenyl-4-carboxylic acid,
- (5) ~~4'-[2-[[(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]ethyl]-2-methyl-1,1'-biphenyl-4-carboxylic acid,~~
- (6) ~~4'-[(2R)-2-[[(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]-amino]propyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid,~~
- (7) (5) 4'-[2-[[(2R)-2-(3-Fluorophenyl)-2-hydroxyethyl]amino]ethyl]-3-propoxy-1,1'-biphenyl-4-carboxylic acid,
- (8) (6) 4'-[(2R)-2-[[(2R)-2-(3-Fluorophenyl)-2-hydroxyethyl]amino]propyl]-3-propoxy-1,1'-biphenyl-4-carboxylic acid,
- (9) (7) 4'-[2-[[(1S,2R)-2-Hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-3-isopropoxy-1,1'-biphenyl-4-carboxylic acid,
and

(10) (8) 4'-[2-[[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-3-isobutyl-1,1'-
biphenyl-4-carboxylic acid,
or a pharmaceutically acceptable salt thereof.

6. (Canceled)

7. (Currently Amended) A pharmaceutical composition which comprises a
therapeutically effective amount of a compound of formula [I] ~~as defined in claim 1~~ claim 5
or a pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable
carriers or excipients.

8. – 10. (Canceled)

11. (Currently Amended) A method for treating pollakiuria or urinary incontinence in
a human or animal in need thereof which comprises administering a therapeutically effective
amount of a compound of formula [I] ~~as defined in claim 1~~ claim 5 or a pharmaceutically
acceptable salt thereof.

12. (Previously Presented) The method of claim 11, wherein said treating pollakiuria
or urinary incontinence is in a human in need thereof.

13. (Previously Presented) The method of claim 11, wherein said treating pollakiuria
or urinary incontinence is in an animal in need thereof.

14. (Currently Amended) The compound of ~~formula [I] as defined in claim 1~~ claim 5, wherein said compound ~~of formula [I]~~ is 4'-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

15. (Currently Amended) The ~~process of claim 6~~ method of claim 12, wherein said compound ~~of formula [I]~~ is 4'-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

16. (Currently Amended) The pharmaceutical composition of claim 7, wherein said compound ~~of formula [I]~~ is 4'-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

17. (Currently Amended) The method of ~~claim 10~~ claim 13, wherein said compound ~~of formula [I]~~ is 4'-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

18. (Currently Amended) The method of claim 11, wherein said compound ~~of formula [I]~~ is 4'-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

19. – 21. (Canceled)

22. (New) The compound of claim 5, wherein said compound is 4'-[(2R)-2-[(2R)-2-Phenyl-2-hydroxyethyl]amino]propyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

23. (New) The compound of claim 5, wherein said compound is 4'-[(2R)-2-[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]-3-isopropoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

24. (New) The compound of claim 5, wherein said compound is 4'-[2-[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]-2,3-dimethyl-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

25. (New) The compound of claim 5, wherein said compound is 4'-[2-[(2R)-2-(3-Fluorophenyl)-2-hydroxyethyl]amino]ethyl]-3-propoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

26. (New) The compound of claim 5, wherein said compound is 4'-[(2R)-2-[(2R)-2-(3-Fluorophenyl)-2-hydroxyethyl]amino]propyl]-3-propoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

27. (New) The compound of claim 5, wherein said compound is 4'-[2-[(1S,2R)-2-Hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-3-isopropoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

28. (New) The compound of claim 5, wherein said compound is 4'-[2-[[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-3-isobutyl-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

29. (New) The pharmaceutical composition of claim 7, wherein said compound is 4'-[[[(2R)-2-[[[(2R)-2-Phenyl-2-hydroxyethyl]amino]propyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

30. (New) The pharmaceutical composition of claim 7, wherein said compound is 4'-[[[(2R)-2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]-3-isopropoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

31. (New) The pharmaceutical composition of claim 7, wherein said compound is 4'-[2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]-2,3-dimethyl-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

32. (New) The pharmaceutical composition of claim 7, wherein said compound is 4'-[2-[[[(2R)-2-(3-Fluorophenyl)-2-hydroxyethyl]amino]ethyl]-3-propoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

33. (New) The pharmaceutical composition of claim 7, wherein said compound is 4'-[[[(2R)-2-[[[(2R)-2-(3-Fluorophenyl)-2-hydroxyethyl]amino]propyl]-3-propoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

34. (New) The pharmaceutical composition of claim 7, wherein said compound is 4'-[2-[[[(1S,2R)-2-Hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-3-isopropoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

35. (New) The pharmaceutical composition of claim 7, wherein said compound is 4'-[2-[[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-3-isobutyl-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

36. (New) The method of claim 11, wherein said compound is 4'-[(2R)-2-[[[(2R)-2-Phenyl-2-hydroxyethyl]amino]propyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

37. (New) The method of claim 11, wherein said compound is 4'-[(2R)-2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]-3-isopropoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

38. (New) The method of claim 11, wherein said compound is 4'-[2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]-2,3-dimethyl-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

39. (New) The method of claim 11, wherein said compound is 4'-[2-[[[(2R)-2-(3-Fluorophenyl)-2-hydroxyethyl]amino]ethyl]-3-propoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

40. (New) The method of claim 11, wherein said compound is 4'-[(2R)-2-[[[(2R)-2-(3-Fluorophenyl)-2-hydroxyethyl]amino]propyl]-3-propoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

41. (New) The method of claim 11, wherein said compound is 4'-[2-[[[(1S,2R)-2-Hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-3-isopropoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

42. (New) The method of claim 11, wherein said compound is 4'-[2-[[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-3-isobutyl-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

43. (New) A method for treating overactive bladder in a human or animal in need thereof which comprises administering a therapeutically effective amount of a compound of claim 5 or a pharmaceutically acceptable salt thereof.

44. (New) The method of claim 43, wherein said treating overactive bladder is in a human in need thereof.

45. (New) The method of claim 43, wherein said treating overactive bladder is in an animal in need thereof.

46. (New) The method of claim 43, wherein said compound is 4'-[2-[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

47. (New) The method of claim 43, wherein said compound is 4'-[(2R)-2-[(2R)-2-Phenyl-2-hydroxyethyl]amino]propyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

48. (New) The method of claim 43, wherein said compound is 4'-[(2R)-2-[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]-3-isopropoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

49. (New) The method of claim 43, wherein said compound is 4'-[2-[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]-2,3-dimethyl-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

50. (New) The method of claim 43, wherein said compound is 4'-[2-[(2R)-2-(3-Fluorophenyl)-2-hydroxyethyl]amino]ethyl]-3-propoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

51. (New) The method of claim 43, wherein said compound is 4'-[(2R)-2-[(2R)-2-(3-Fluorophenyl)-2-hydroxyethyl]amino]propyl]-3-propoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

52. (New) The method of claim 43, wherein said compound is 4'-[2-[[[(1S,2R)-2-Hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-3-isopropoxy-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

53. (New) The method of claim 43, wherein said compound is 4'-[2-[[[(2R)-2-Hydroxy-2-phenylethyl]amino]ethyl]-3-isobutyl-1,1'-biphenyl-4-carboxylic acid or a pharmaceutically acceptable salt thereof.

SUPPORT FOR THE AMENDMENTS

Claims 8 and 9 were previously canceled.

Claims 1-4, 6, 10, and 19-21 are presently canceled.

Claims 5, 7, 11, and 14-18 have been amended.

Claims 22-53 have been added.

The amendment of Claims 5, 7, 11, and 14-18 and the introduction of new Claims 22-42 is supported by the originally presented claims and the Examples of the present application. New Claims 43-53 are supported by original Claims 5 and 11, as well as the specification at page 12, line 27 to page 13, line 18.

No new matter has been added by the present amendments.